Explore the words cloud of the MOOAC project. It provides you a very rough idea of what is the project "MOOAC" about.
The following table provides information about the project.
Coordinator |
ELVESYS
Organization address contact info |
Coordinator Country | France [FR] |
Total cost | 185˙076 € |
EC max contribution | 185˙076 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2016 |
Funding Scheme | MSCA-IF-EF-SE |
Starting year | 2018 |
Duration (year-month-day) | from 2018-04-01 to 2020-03-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | ELVESYS | FR (PARIS) | coordinator | 185˙076.00 |
Drug development is stuck in an innovation gap, in which it incurs staggering expenses and takes many, ten to fifteen, years to get a drug to market, furthermore, during the process many animals are sacrificed in preclinical work, and in the end many times the results from the animal studies does not accurately predict what will happen in humans, resulting in failures, delays, and recalled drugs. There is currently a gap in the preclinical testing platform for therapeutics. Organ-on-a-chip technologies of closing this gap, and have the potential of curtailing the high experimental costs and complexities associated with in vivo studies, and eventually evolving into next generation tools for therapeutic validation and development. We propose that by using a multi-compartment microfluidic platform, while integrating synthetic biointeractive hydrogels into and between the compartments, we will be able to produce a multi-organ-on-a-chip which recapitulates organ-like functions in each compartment and a vascular-similar conduit system between compartments to produce an early stage human on-a-chip for future therapeutic assessment and development applications. This project aims to develop a preliminary human-on-a-chip device, initially focusing on a heart-, and liver-on-a-chip and an endothelialized-conduit system between and through the two organ compartments. Successful production of this platform will improve the therapeutic and pharmaceutical development pipeline, while also minimizing our reliance on animal testing in accordance with the needs and guidelines within the EU. The long term implications of this work would result in increasing the throughput of therapeutics, directly minimizing the cost of drug development and increasing the efficiency. This would lead to lowered economic burden to produce drugs, as well as quicker turn around, having large implications on improving the quality of life in globally.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOOAC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MOOAC" are provided by the European Opendata Portal: CORDIS opendata.